Dossier assessment
Cannabidiol (seizures in tuberous sclerosis complex) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Report documents
-
Dossier assessment
Cannabidiol (seizures in tuberous sclerosis complex) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Project details
- Project no.
- G21-17
- Commission
- Commission awarded on 14.05.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Children's and adolescents' health
- Note
-
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page
of the GBA Website.
Connected Projects
-
Dossier assessment
Cannabidiol (Lennox-Gastaut syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Cannabidiol (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Cannabidiol for the treatment of Dravet syndrome in patients from the age of 2 years - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Cannabidiol for the treatment of Lennox-Gastaut syndrome in patients from the age of 2 years - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Cannabidiol (tuberous sclerosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cannabidiol (Lennox Gastaut syndrome) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cannabidiol (Dravet syndrome) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed